Watch Out For A Dangerous One-Two Punch

December 2004
RN;Dec2004, Vol. 67 Issue 12, p72
Academic Journal
Reports on Savient Pharmaceuticals Inc.'s issuance of a safety alert to nurses and other healthcare professionals regarding a possibly serious interaction between its anabolic steroid oxandroline (Oxandrin) and warfarin (Coumadin). Use of oxadrolone to promote weight gain; Evidence that concurrent dosing of oxandroline and warfarin may result in large increases in prothrombin time.


Related Articles

  • Note interaction of oxandrolone, warfarin.  // Drug Topics;5/17/2004, Vol. 148 Issue 10, p8 

    Reports that the Savient Pharmaceuticals recently notified healthcare professionals of a drug interaction between oxandrolone USP and warfarin.

  • Amitriptyline and flunarizine: hormones behind weight gain.  // Reactions Weekly;1/7/2006, Issue 1083, p5 

    This article discusses research being done on the effects of amitriptyline and flunarizine on weight gain and serum leptin. It references a study by M. S. Berilgen et al published in a November 2005 issue of "Cephalalgia." It investigates the relationship between weight gain and the use of...

  • Clozapine/olanzapine/risperidone.  // Reactions Weekly;2/11/2006, Issue 1088, p11 

    This article presents case reports involving patients who developed weight gain during treatment with atypical antipsychotics for schizophrenia. It provides a background on the medical history of the patient. It describes the symptoms presented by the patient. It offers information on...

  • Warfarin interaction.  // Reactions Weekly;3/15/2008, Issue 1193, p30 

    The article presents case reports of four women who are receiving warfarin therapy and experienced an increase in their respective baseline international normalized ratio (INR) after starting concomitant noscapine. According to the case reports, each patient's INR increased from baseline after...

  • Enoxaparin sodium/heparin.  // Reactions Weekly;5/16/2009, Issue 1252, p20 

    The article describes the case of an old man who developed heparin-induced thrombocytopenia (HIT) in association with implantation of an expanded polytetrafluoroethylene graft, bonded with unfractionated heparin (UFH), for infrainguinal revascularisation. The patient also received UFH...

  • Bosutinib/warfarin interaction.  // Reactions Weekly;Nov2015, Vol. 1577 Issue 1, p67 

    The article presents a case study of an 84-year-old man who developed pulmonary haemorrhage following treatment with bosutinib and warfarin for chronic myelogenous leukaemia.

  • Drug advisory: the interaction between warfarin and vaginal miconazole. Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;10/2/2001, Vol. 165 Issue 7, p938 

    Focuses on the warnings issued by the United States Food and Drug Administration and Health Canada that prothrombin times can increase for patients receiving antiocoagulation therapy who also use vaginal miconazole. Description of the interaction between warfarin and vaginal miconazole; Adverse...

  • HI-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs. Kroeze, Wesley K.; Hufeisen, Sandra J.; Popadak, Beth A.; Renock, Sean M.; Steinberg, SeAnna; Ernsberger, Paul; Jayathilake, Karu; Meltzer, Herbert Y.; Roth, Bryan L. // Neuropsychopharmacology;Mar2003, Vol. 28 Issue 3, p519 

    As a result of superior efficacy and overall tolerability, atypical antipsychotic drugs have become the treatment of choice for schizophrenia and related disorders, despite their side effects. Weight gain is a common and potentially serious complication of some antipsychotic drug therapy, and...

  • The predictivity of preliminary embryo-fetal development (EFD) studies: results of a retrospective survey in Japanese pharmaceutical companies. Okahashi, Noriko; Ikeda, Takashi; Kai, Shuichi; Komatsu, Shinichi; Matsui, Hajime; Yamashita, Yasuhiro; Yamamoto, Keiji; Sagami, Fumio // Journal of Toxicological Sciences;Feb2010, Vol. 35 Issue 1, p21 

    To explore the predictivity of dose range-finding (DRF) studies, we conducted a survey by sending out questionnaires to 72 Japanese pharmaceutical companies. The survey yielded data for 108 and 85 compounds for which any embryo-fetal development (EFD) toxicities were observed in the definitive...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics